vs

Side-by-side financial comparison of ENANTA PHARMACEUTICALS INC (ENTA) and Rhinebeck Bancorp, Inc. (RBKB). Click either name above to swap in a different company.

ENANTA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($18.6M vs $13.5M, roughly 1.4× Rhinebeck Bancorp, Inc.). Rhinebeck Bancorp, Inc. runs the higher net margin — 17.3% vs -64.1%, a 81.4% gap on every dollar of revenue. On growth, Rhinebeck Bancorp, Inc. posted the faster year-over-year revenue change (1701.1% vs 9.8%). Rhinebeck Bancorp, Inc. produced more free cash flow last quarter ($10.9M vs $-11.8M). Over the past eight quarters, Rhinebeck Bancorp, Inc.'s revenue compounded faster (14.0% CAGR vs 4.5%).

Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.

Rhinebeck Bancorp, Inc. is a US regional bank holding company based in New York. It operates Rhinebeck Bank, offering retail and commercial banking services including deposit accounts, loans, mortgages and wealth management, mainly serving consumers and small-to-medium businesses across New York's Hudson Valley region.

ENTA vs RBKB — Head-to-Head

Bigger by revenue
ENTA
ENTA
1.4× larger
ENTA
$18.6M
$13.5M
RBKB
Growing faster (revenue YoY)
RBKB
RBKB
+1691.3% gap
RBKB
1701.1%
9.8%
ENTA
Higher net margin
RBKB
RBKB
81.4% more per $
RBKB
17.3%
-64.1%
ENTA
More free cash flow
RBKB
RBKB
$22.7M more FCF
RBKB
$10.9M
$-11.8M
ENTA
Faster 2-yr revenue CAGR
RBKB
RBKB
Annualised
RBKB
14.0%
4.5%
ENTA

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ENTA
ENTA
RBKB
RBKB
Revenue
$18.6M
$13.5M
Net Profit
$-11.9M
$2.3M
Gross Margin
Operating Margin
-60.5%
21.7%
Net Margin
-64.1%
17.3%
Revenue YoY
9.8%
1701.1%
Net Profit YoY
46.4%
188.0%
EPS (diluted)
$-0.42
$0.21

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ENTA
ENTA
RBKB
RBKB
Q4 25
$18.6M
$13.5M
Q3 25
$15.1M
$14.0M
Q2 25
$18.3M
$13.1M
Q1 25
$14.9M
$12.8M
Q4 24
$17.0M
$750.0K
Q3 24
$14.6M
$773.0K
Q2 24
$18.0M
$10.7M
Q1 24
$17.1M
$10.4M
Net Profit
ENTA
ENTA
RBKB
RBKB
Q4 25
$-11.9M
$2.3M
Q3 25
$-18.7M
$2.7M
Q2 25
$-18.3M
$2.7M
Q1 25
$-22.6M
$2.3M
Q4 24
$-22.3M
$-2.7M
Q3 24
$-28.8M
$-8.1M
Q2 24
$-22.7M
$975.0K
Q1 24
$-31.2M
$1.1M
Operating Margin
ENTA
ENTA
RBKB
RBKB
Q4 25
-60.5%
21.7%
Q3 25
-121.6%
23.9%
Q2 25
-103.2%
26.6%
Q1 25
-164.3%
22.9%
Q4 24
-138.8%
-444.9%
Q3 24
-204.4%
-1332.3%
Q2 24
-134.6%
11.8%
Q1 24
-192.1%
13.9%
Net Margin
ENTA
ENTA
RBKB
RBKB
Q4 25
-64.1%
17.3%
Q3 25
-123.6%
19.3%
Q2 25
-99.7%
20.8%
Q1 25
-151.7%
17.9%
Q4 24
-131.4%
-353.9%
Q3 24
-197.3%
-1042.9%
Q2 24
-126.1%
9.2%
Q1 24
-182.7%
10.8%
EPS (diluted)
ENTA
ENTA
RBKB
RBKB
Q4 25
$-0.42
$0.21
Q3 25
$-0.88
$0.25
Q2 25
$-0.85
$0.25
Q1 25
$-1.06
$0.21
Q4 24
$-1.05
$-0.24
Q3 24
$-1.36
$-0.75
Q2 24
$-1.07
$0.09
Q1 24
$-1.47
$0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ENTA
ENTA
RBKB
RBKB
Cash + ST InvestmentsLiquidity on hand
$37.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$126.6M
$136.9M
Total Assets
$329.5M
$1.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ENTA
ENTA
RBKB
RBKB
Q4 25
$37.4M
Q3 25
$32.3M
Q2 25
$44.8M
Q1 25
$60.2M
Q4 24
$84.3M
Q3 24
$37.2M
Q2 24
$35.8M
Q1 24
$63.5M
Stockholders' Equity
ENTA
ENTA
RBKB
RBKB
Q4 25
$126.6M
$136.9M
Q3 25
$64.7M
$133.0M
Q2 25
$79.3M
$129.0M
Q1 25
$93.5M
$126.0M
Q4 24
$111.8M
$121.8M
Q3 24
$128.8M
$122.7M
Q2 24
$148.9M
$116.2M
Q1 24
$166.1M
$114.3M
Total Assets
ENTA
ENTA
RBKB
RBKB
Q4 25
$329.5M
$1.3B
Q3 25
$280.7M
$1.3B
Q2 25
$301.0M
$1.3B
Q1 25
$323.0M
$1.3B
Q4 24
$348.6M
$1.3B
Q3 24
$376.7M
$1.3B
Q2 24
$398.8M
$1.3B
Q1 24
$413.6M
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ENTA
ENTA
RBKB
RBKB
Operating Cash FlowLast quarter
$-11.7M
$11.7M
Free Cash FlowOCF − Capex
$-11.8M
$10.9M
FCF MarginFCF / Revenue
-63.6%
80.6%
Capex IntensityCapex / Revenue
0.8%
6.3%
Cash ConversionOCF / Net Profit
5.03×
TTM Free Cash FlowTrailing 4 quarters
$-18.5M
$19.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ENTA
ENTA
RBKB
RBKB
Q4 25
$-11.7M
$11.7M
Q3 25
$-6.5M
$2.2M
Q2 25
$17.5M
$2.4M
Q1 25
$-13.5M
$4.3M
Q4 24
$-16.8M
$8.5M
Q3 24
$-10.4M
$-3.6M
Q2 24
$-14.8M
$12.0M
Q1 24
$-28.6M
$-3.5M
Free Cash Flow
ENTA
ENTA
RBKB
RBKB
Q4 25
$-11.8M
$10.9M
Q3 25
$-7.9M
$2.0M
Q2 25
$17.4M
$2.2M
Q1 25
$-16.0M
$4.2M
Q4 24
$-25.5M
$7.7M
Q3 24
$-19.4M
$-3.6M
Q2 24
$-21.3M
$11.8M
Q1 24
$-30.3M
$-3.7M
FCF Margin
ENTA
ENTA
RBKB
RBKB
Q4 25
-63.6%
80.6%
Q3 25
-52.5%
14.5%
Q2 25
94.7%
17.2%
Q1 25
-107.4%
32.8%
Q4 24
-150.6%
1023.9%
Q3 24
-132.5%
-469.0%
Q2 24
-118.6%
111.1%
Q1 24
-177.5%
-36.0%
Capex Intensity
ENTA
ENTA
RBKB
RBKB
Q4 25
0.8%
6.3%
Q3 25
9.6%
1.4%
Q2 25
0.8%
1.4%
Q1 25
17.0%
0.9%
Q4 24
51.6%
105.5%
Q3 24
61.3%
6.3%
Q2 24
36.4%
1.2%
Q1 24
9.8%
2.3%
Cash Conversion
ENTA
ENTA
RBKB
RBKB
Q4 25
5.03×
Q3 25
0.83×
Q2 25
0.89×
Q1 25
1.89×
Q4 24
Q3 24
Q2 24
12.27×
Q1 24
-3.12×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons